HomeCompareHOLX vs RMD

HOLX vs RMD: Dividend Comparison 2026

HOLX yields 2.65% · RMD yields 1.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RMD wins by $8.1K in total portfolio value· pulled ahead in Year 5
10 years
HOLX
HOLX
● Live price
2.65%
Share price
$75.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$314.03
Full HOLX calculator →
RMD
RMD
● Live price
1.06%
Share price
$220.03
Annual div
$2.33
5Y div CAGR
35.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$3,288.25
Full RMD calculator →

Portfolio growth — HOLX vs RMD

📍 RMD pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHOLXRMD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HOLX + RMD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HOLX pays
RMD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HOLX
Annual income on $10K today (after 15% tax)
$225.02/yr
After 10yr DRIP, annual income (after tax)
$266.93/yr
RMD
Annual income on $10K today (after 15% tax)
$90.01/yr
After 10yr DRIP, annual income (after tax)
$2,795.01/yr
At 15% tax rate, RMD beats the other by $2,528.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HOLX + RMD for your $10,000?

HOLX: 50%RMD: 50%
100% RMD50/50100% HOLX
Portfolio after 10yr
$27.7K
Annual income
$1,801.13/yr
Blended yield
6.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HOLX right now

HOLX
Analyst Ratings
18
Buy
23
Hold
1
Sell
Consensus: Hold
Price Target
$77.80
+3.0% upside vs current
Range: $76.00 — $79.00
Altman Z
4.2
Piotroski
7/9
RMD
Analyst Ratings
16
Buy
14
Hold
5
Sell
Consensus: Buy
Price Target
$295.88
+34.5% upside vs current
Range: $265.00 — $345.00
Altman Z
11.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HOLX buys
0
RMD buys
0
No recent congressional trades found for HOLX or RMD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHOLXRMD
Forward yield2.65%1.06%
Annual dividend / share$2.00$2.33
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%35.9%
Portfolio after 10y$23.6K$31.7K
Annual income after 10y$314.03$3,288.25
Total dividends collected$2.9K$10.4K
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusHoldBuy
Analyst price target$77.80$295.88

Year-by-year: HOLX vs RMD ($10,000, DRIP)

YearHOLX PortfolioHOLX Income/yrRMD PortfolioRMD Income/yrGap
1$10,965$264.73$10,844$143.91+$121.00HOLX
2$12,004$271.27$11,801$198.21+$203.00HOLX
3$13,121$277.55$12,901$273.96+$220.00HOLX
4$14,323$283.54$14,185$380.39+$138.00HOLX
5← crossover$15,615$289.27$15,709$531.20$94.00RMD
6$17,003$294.73$17,556$747.16$553.00RMD
7$18,493$299.93$19,845$1,060.53$1.4KRMD
8$20,093$304.87$22,757$1,522.63$2.7KRMD
9$21,809$309.57$26,567$2,217.64$4.8KRMD
10$23,649$314.03$31,715$3,288.25$8.1KRMD

HOLX vs RMD: Complete Analysis 2026

HOLXHealthcare

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Full HOLX Calculator →

RMDHealthcare

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Full RMD Calculator →
📬

Get this HOLX vs RMD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HOLX vs SCHDHOLX vs JEPIHOLX vs OHOLX vs KOHOLX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.